SCHEMBL27660964

SCHEMBL27660964

CCc1c(C(C=O)CBr)cnn1-c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A3 Q92570 1/20 0.50
MAPT P10636 8/20 0.36
ALDH1A1 P00352 7/20 0.36
NPSR1 Q6W5P4 3/20 0.36
RXFP1 Q9HBX9 2/20 0.36
PPARG P37231 1/20 0.36
BLM P54132 1/20 0.36
NCOA2 Q15596 1/20 0.36
NCOA1 Q15788 1/20 0.36
RAB9A P51151 6/20 0.35
NPC1 O15118 4/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
LMNA P02545 2/20 0.35
HTT P42858 1/20 0.35
PAX8 Q06710 1/20 0.35
HIF1A Q16665 1/20 0.35
HPGD P15428 3/20 0.34
MAPK1 P28482 3/20 0.34
TDP1 Q9NUW8 1/20 0.34
NFKB1 P19838 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27681019 0.82 NR4A3 (0.54) NR4A3MAPTALDH1A1NPSR1RXFP1
SCHEMBL27660961 0.80 NR4A3 (0.58) NR4A3MAPTALDH1A1RAB9ANPC1
SCHEMBL12340468 0.77 NR4A3 (0.56) NR4A3MAPTALDH1A1NPSR1RXFP1
SCHEMBL4041244 0.76 NR4A3 (0.59) NR4A3MAPTALDH1A1NPSR1RXFP1
SCHEMBL27681018 0.74 NR4A3 (0.61) NR4A3MAPTALDH1A1RAB9ANPC1
SCHEMBL4037627 0.73 NR4A3 (0.59) NR4A3MAPTALDH1A1NPSR1RXFP1
SCHEMBL12338161 0.72 NR4A3 (0.66) NR4A3MAPTALDH1A1NPSR1RXFP1
SCHEMBL27596217 0.69 GABRA1 (0.38) MAPTNPSR1NFKB1TSHRL3MBTL1
SCHEMBL18265951 0.69 NR4A3 (0.61) NR4A3MAPTALDH1A1NPSR1RXFP1
SCHEMBL4036784 0.69 NR4A3 (0.74) NR4A3MAPTALDH1A1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1930144-A 3-'4-heterocyclyl -1,2,3,-triazol-1-yl!-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases BOEHRINGER INGELHEIM PHARMA (US) 2007-03-14 CN disclosed